{
    "xml": "<topic id=\"PHP4156\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/tolbutamide\" basename=\"tolbutamide\" title=\"TOLBUTAMIDE\">\n<title>TOLBUTAMIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_275\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/sulfonylureas/tolbutamide\">Tolbutamide</xref>\n</p>\n<data name=\"vtmid\">33124007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_606020038\" title=\"Sulfonylureas\">Sulfonylureas</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34524\" title=\"SULFONYLUREAS\" namespace=\"/drug-classes/sulfonylureas\">SULFONYLUREAS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP55554\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/drugs/tolbutamide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.5&#8211;1.5&#8239;g daily in divided doses (max. per dose 2&#8239;g), dose to be taken with or immediately after meals, alternatively 0.5&#8211;1.5&#8239;g once daily (max. per dose 2&#8239;g), dose to be taken with or immediately after breakfast.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55633\" outputclass=\"contraindications\" rev=\"1.17\" parent=\"/drugs/tolbutamide\">\n<title>Contra-indications</title>\n<body>\r\n<section outputclass=\"contraindications\">\r\n<p>\r\n<ph outputclass=\"contraindication\">Avoid where possible in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP55543\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/tolbutamide\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55487\" outputclass=\"sideEffects\" rev=\"1.7\" parent=\"/drugs/tolbutamide\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Headache</ph>; <ph outputclass=\"sideEffect\">tinnitus</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55536\" outputclass=\"pregnancy\" parent=\"/drugs/tolbutamide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55673\" outputclass=\"breastFeeding\" parent=\"/drugs/tolbutamide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>The use of sulfonylureas in breast-feeding should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55511\" outputclass=\"renalImpairment\" parent=\"/drugs/tolbutamide\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>If necessary, the short-acting drug tolbutamide can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP4156-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tolbutamide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76142\" title=\"Tablet\" namespace=\"/drugs/tolbutamide/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"1\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_275\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/sulfonylureas/tolbutamide\" title=\"Tolbutamide\" count=\"1\" rel=\"link\">Tolbutamide</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34524\" namespace=\"/drug-classes/sulfonylureas\" title=\"SULFONYLUREAS\" count=\"1\" rel=\"link\">SULFONYLUREAS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76142\" namespace=\"/drugs/tolbutamide/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP4156",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/tolbutamide",
    "basename": "tolbutamide",
    "title": "TOLBUTAMIDE",
    "interactants": [
        {
            "id": "bnf_int_275",
            "label": "Tolbutamide"
        }
    ],
    "vtmid": "33124007",
    "drugClassification": [
        "Sulfonylureas"
    ],
    "inheritsFromClass": [
        "SULFONYLUREAS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Type 2 diabetes mellitus",
                        "html": "Type 2 diabetes mellitus"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "0.5&#8211;1.5 g daily in divided doses (max. per dose 2 g), dose to be taken with or immediately after meals, alternatively 0.5&#8211;1.5 g once daily (max. per dose 2 g), dose to be taken with or immediately after breakfast.",
                        "html": "<p>0.5&#8211;1.5&#8239;g daily in divided doses (max. per dose 2&#8239;g), dose to be taken with or immediately after meals, alternatively 0.5&#8211;1.5&#8239;g once daily (max. per dose 2&#8239;g), dose to be taken with or immediately after breakfast.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Avoid where possible in Acute porphyrias",
                "html": "Avoid where possible in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).",
                "html": "<p>Appendix 1 (antidiabetics).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Headache",
                        "html": "Headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tinnitus",
                        "html": "tinnitus",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.",
                "html": "<p>The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "The use of sulfonylureas in breast-feeding should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.",
                "html": "<p>The use of sulfonylureas in breast-feeding should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "If necessary, the short-acting drug tolbutamide can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.",
                "html": "<p>If necessary, the short-acting drug tolbutamide can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76142",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_275",
                "label": "Tolbutamide",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34524",
                "label": "SULFONYLUREAS",
                "type": "drugClass"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76142",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}